Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding
Article in Immunity Inflammation and Disease (February 2024)
The most recent citing publications are shown below. View all 32 publications that cite this research output on Dimensions.
Article in Immunity Inflammation and Disease (February 2024)
Article in Rheumatology Science and Practice (October 2023)
Article in Modern Rheumatology (May 2023)